BioCentury
ARTICLE | Clinical News

ISIS-SGLT2Rx: Phase I started

February 9, 2009 8:00 AM UTC

Isis began a double-blind, placebo-controlled, dose-escalation Phase I trial in 84 healthy volunteers. ...